Dermatology--24th Hawaii Seminar. 7-12 February 2000, Big Island, HI, USA [0.03%]
皮肤病学——第24届夏威夷研讨会。2000年2月7-12日，美国夏威夷州大岛
S J Bashir,A L Chew,H I Maibach
S J Bashir
At this seminar, several encouraging developments were demonstrated in various areas of dermatology practice. Much attention was focused on topical tacrolimus, the US approval of which, for the treatment of atopic dermatitis is much anticip...
Australian Neuroscience Society--20th Annual Meeting. 30 January-2 February 2000, Melbourne, Australia [0.03%]
澳大利亚神经科学协会第20届年会 2000年1月30日至2月2日在澳大利亚墨尔本举行
M C Bellingham
M C Bellingham
This meeting presented a large array of high quality neuroscience research, some of which held possible relevance for therapeutic development. The potential use of multipotent neural stem cells harvested from adult brain for transplantation...
More appropriate vaccines [0.03%]
更合适的疫苗
T Jones
T Jones
P K Yeung
P K Yeung
ATIII LLC, a joint venture between Genzyme Transgenics (GTC) and Genzyme General, is developing transgenic recombinant human antithrombin III (rhAT-III) as a potential treatment for sepsis and other disorders involving thrombosis. It is in ...
S Beckett
S Beckett
Esteve is developing E-5842, a sigma1 opioid receptor ligand, as a potential therapy for psychosis. It has completed phase I trials [344879,346244]. As of May 1999, the site and protocol for phase II schizophrenia trials in the UK had been ...
U Thatte
U Thatte
CPC-211 is under development by Questcor (formerly Cypros) as a potential treatment for stroke and closed head injury. Phase II trials have commenced for both indications. In June 1999, it was granted Orphan Drug status [329979]. In July 19...
Cardiac-derived stem cells [0.03%]
心脏源性干细胞
T A Deisher
T A Deisher
Current scientific dogma holds that cardiomyocyte stem cells do not exist in the adult mammalian heart, and furthermore, that there is little, if any, potential for the regeneration of damaged myocardium. In order to approach this topic, I ...
HLA-binding peptides as a therapeutic approach for chronic HIV infection [0.03%]
用于治疗慢性HIV感染的HLA结合肽疗法
A Sette,R Chesnut,B Livingston et al.
A Sette et al.
Herein, we describe the Epimmune approach to prophylaxis and development of a multi-epitope vaccine for immunotherapy of HIV-1 infection. The central strategy of our program is to induce cellular immune responses, cytotoxic T-lymphocytes (C...
D G Lloyd,M J Meegan
D G Lloyd